Patient and disease characteristics
| Characteristic . | Data (N = 612) . |
|---|---|
| Age and follow-up, median (range), y | |
| Age at time of transplant | 60 (21-78) |
| Follow-up | 6.0 (1.0-16.4) |
| Diagnosis, n (%) | |
| AML | 193 (32) |
| De novo AML | 139 (23) |
| Secondary AML* | 54 (9) |
| MDS† | 94 (15) |
| Myelofibrosis | 9 (1) |
| CML | 12 (2) |
| ALL | 14 (2) |
| CLL | 80 (13) |
| NHL | 175 (29) |
| Diffuse large B-cell lymphoma | 66 (11) |
| Mantle cell lymphoma | 53 (9) |
| Follicular lymphoma | 22 (4) |
| Other B-cell lymphoma‡ | 12 (2) |
| T-cell lymphoma§ | 22 (4) |
| HL | 35 (6) |
| Lymphoma with prior autologous HCT | 116/210 (55) |
| Donor, n (%) | |
| HLA-MRD | 271 (44) |
| HLA-MUD | 250 (41) |
| HLA-MMUD | 89 (15) |
| HLA-MMRD | 2 (0.3) |
| DRI, n (%) | |
| Low risk | 140 (23) |
| Intermediate risk | 289 (47) |
| High risk | 167 (27) |
| Very high risk | 16 (3) |
| CI, n (%) | |
| HCT-CI 0 | 178 (29) |
| HCT-CI 1 | 112 (18) |
| HCT-CI 2 | 113 (18) |
| HCT-CI 3 | 104 (17) |
| HCT-CI ≥4 | 105 (17) |
| Donor and recipient sex, n (%) | |
| Male donor, male recipient | 195 (32) |
| Male donor, female recipient | 143 (23) |
| Female donor, male recipient | 161 (26) |
| Female donor, female recipient | 113 (18) |
| CMV serologic status, n (%) | |
| Donor and/or recipient seropositive | 444 (73) |
| Donor and recipient seronegative | 168 (27) |
| Characteristic . | Data (N = 612) . |
|---|---|
| Age and follow-up, median (range), y | |
| Age at time of transplant | 60 (21-78) |
| Follow-up | 6.0 (1.0-16.4) |
| Diagnosis, n (%) | |
| AML | 193 (32) |
| De novo AML | 139 (23) |
| Secondary AML* | 54 (9) |
| MDS† | 94 (15) |
| Myelofibrosis | 9 (1) |
| CML | 12 (2) |
| ALL | 14 (2) |
| CLL | 80 (13) |
| NHL | 175 (29) |
| Diffuse large B-cell lymphoma | 66 (11) |
| Mantle cell lymphoma | 53 (9) |
| Follicular lymphoma | 22 (4) |
| Other B-cell lymphoma‡ | 12 (2) |
| T-cell lymphoma§ | 22 (4) |
| HL | 35 (6) |
| Lymphoma with prior autologous HCT | 116/210 (55) |
| Donor, n (%) | |
| HLA-MRD | 271 (44) |
| HLA-MUD | 250 (41) |
| HLA-MMUD | 89 (15) |
| HLA-MMRD | 2 (0.3) |
| DRI, n (%) | |
| Low risk | 140 (23) |
| Intermediate risk | 289 (47) |
| High risk | 167 (27) |
| Very high risk | 16 (3) |
| CI, n (%) | |
| HCT-CI 0 | 178 (29) |
| HCT-CI 1 | 112 (18) |
| HCT-CI 2 | 113 (18) |
| HCT-CI 3 | 104 (17) |
| HCT-CI ≥4 | 105 (17) |
| Donor and recipient sex, n (%) | |
| Male donor, male recipient | 195 (32) |
| Male donor, female recipient | 143 (23) |
| Female donor, male recipient | 161 (26) |
| Female donor, female recipient | 113 (18) |
| CMV serologic status, n (%) | |
| Donor and/or recipient seropositive | 444 (73) |
| Donor and recipient seronegative | 168 (27) |
MMRD, mismatched related donor.
Patients with an antecedent myeloid malignancy or therapy-related myeloid neoplasm.
Includes patients with chronic myelomonocytic leukemia (n = 4) and MDS/myeloproliferative neoplasm unclassifiable (n = 2).
Includes patients with marginal zone lymphoma (n = 7) and lymphoplasmacytic lymphoma (n = 5).
Includes patients with angioimmunoblastic T-cell lymphoma (n = 8), peripheral T-cell lymphoma not otherwise specified (n = 6), anaplastic large cell lymphoma (n = 5), subcutaneous panniculitis-like T-cell lymphoma (n = 2), and extranodal NKT-cell lymphoma (n = 1).